Kirin Holdings ramps up immunity-support production amid heightened consumer interest
The company will spend about US$8m expanding the manufacturing capabilities of its proprietary lactococcus lactis strain plasma.
The company will spend about US$8m expanding the manufacturing capabilities of its proprietary lactococcus lactis strain plasma.